Education
About Us
Working with TipRanks
Follow Us
Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.69
Previous CloseN/A
Volume34.30K
Average Volume (3M)149.45K
Market Cap
AU$21.58M
Enterprise ValueAU$2.77M
Total Cash (Recent Filing)AU$29.87M
Total Debt (Recent Filing)AU$653.00K
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$18.85M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low debt-to-equity ratio provides durable financial flexibility: it reduces refinancing risk, supports investment in regulatory approvals or commercial rollouts, and gives time for the business to scale consumable sales without heavy interest burdens despite current losses.
Consumable-driven, Recurring Revenue ModelSelling consumable PCR test kits creates a durable recurring revenue stream: as installed customers run tests, kit volumes scale. Proprietary 3base™ technology and distributor/direct lab channels support stickiness and potential margin capture as utilization and menu breadth increase over time.
Positive Recent Revenue TrendConsistent recent revenue growth signals improving commercial traction and broader assay adoption. For an IVD company that monetizes consumables, sustained top-line expansion can compound recurring sales, improving operating leverage and strengthening long-term cash generation if maintained.
Bears Say
Persistent Negative ProfitabilityOngoing unprofitability is a structural concern: persistent negative margins limit retained earnings and reinvestment capacity, increase reliance on external capital, and constrain the firm's ability to fund commercial expansion or absorb reimbursement and pricing pressures over the medium term.
Negative Operating And Free Cash FlowContinued negative operating cash flow erodes liquidity and forces dependence on financing or equity raises. This weak cash generation undermines the firm's ability to scale distribution, support validation/market access activities, and sustain operations without dilutive or costly external funding.
Demand Seasonality And Outbreak RelianceHeavy reliance on seasonal respiratory demand and outbreak-driven spikes creates structural revenue volatility. This variability complicates capacity planning, purchasing predictability for labs, and revenue visibility, making margin stability and long-term forecasting more challenging for management.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.10 and its highest was AU$0.69 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$21.58M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 170 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.35%
12-Months-Change
Fundamentals
Return on Equity
-36.16%
Trailing 12-Months
Asset Growth
-18.81%
Trailing 12-Months
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Inoviq Ltd
―